PlainPill

Ipamorelin vs MK-2866 for weight loss

Short answer: For weight loss, users rate them about the same: 93% report improvement with Ipamorelin (43 reports) and 89% with MK-2866 (80 reports).

Ipamorelin has 0 meta-analyses and 2 randomized trials on PubMed; MK-2866 has 0 and 0.

Based on 378 reports about Ipamorelin and 612 about MK-2866. Not medical advice.

Ipamorelin
Peptide
MK-2866
SARM
User score1833
Verdict
Mostly positive
Mixed
Positive
of reports that state an outcome
63%39%
Reports378612
ResearchCResearch: LimitedDResearch: None
Meta-analyses / RCTs0 / 20 / 0
Mainly used for
Weight loss
% reporting improvement
93% (43)89% (80)
Appetite
% reporting improvement
25% (12)62% (8)
Focus
% reporting improvement
100% (5)71% (7)
Energy
% reporting improvement
88% (17)54% (37)
Sleep
% reporting improvement
77% (65)20% (20)
Anxiety
% reporting improvement
—33% (9)
Mood
% reporting improvement
100% (8)63% (49)
Performance
% reporting improvement
82% (33)88% (192)
Recovery
% reporting improvement
88% (43)97% (60)
Pain & inflammation
% reporting improvement
100% (13)70% (27)
Digestion
% reporting improvement
33% (3)—
Libido
% reporting improvement
—31% (45)
Hormones
% reporting improvement
72% (18)4% (82)
Blood sugar
% reporting improvement
0% (3)—
Heart & lipids
% reporting improvement
—0% (8)
Skin & hair
% reporting improvement
91% (11)33% (6)
Common side effectsinsomnia, flushing, water retention, fatiguesuppression, fatigue, insomnia, headache
Typical dose reportedNot listedNot listed
Ipamorelin
What a user said
“CJC-1295, Ipamorelin, rHGH all help. Helped me recover from Phenibut overuse and dependence, and heavy stimulants.”
Full Ipamorelin profile →
MK-2866
What a user said
“I've taken LDG-4033 and Ostarine from Ceretropic and noticed slight psychoactive effects from both, immediately (within 30 minutes after dosing).”
Full MK-2866 profile →

Related comparisons

Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate